Maysiglu (Sitagliptin)

Sitagliptin blocks the enzyme dipeptidyl peptidase‑4 (DPP‑4), preventing the breakdown of incretin hormones GLP‑1 and GIP. Higher incretin levels stimulate insulin release and suppress glucagon when glucose is elevated, helping to lower blood glucose.

The appropriate dose of Maysiglu is determined by the prescribing healthcare professional based on the individual’s clinical condition, renal function, and response to therapy. Patients should follow the prescriber’s instructions exactly.

Safety of sitagliptin in pregnancy and lactation has not been fully established. Women who are pregnant, planning to become pregnant, or breastfeeding should discuss potential risks and benefits with their healthcare provider before using Maysiglu.

To request Maysiglu, submit an enquiry on the product page at gnhindia.com with the required quantity. GNH India supplies hospitals, pharmacies and procurement teams worldwide, verifies trade or institutional credentials, and then provides pricing, availability, shipping details and any necessary import documentation.

Maysiglu belongs to the DPP‑4 inhibitor class, offering glucose‑dependent insulin release with a low risk of hypoglycemia compared with sulfonylureas. Unlike metformin, it does not affect gastrointestinal absorption, and it can be combined with many other antidiabetic agents for additive effect.

Store Maysiglu at room temperature, preferably below 25 °C. Keep the tablets in the original container, protect them from moisture, heat and direct sunlight to maintain potency throughout the shelf life.

Maysiglu is taken orally, usually once daily, with or without food. The tablet should be swallowed whole with water and not crushed or chewed unless otherwise directed by a healthcare professional.

Serious adverse events include acute pancreatitis, severe hypersensitivity reactions such as anaphylaxis, and marked hypoglycemia when used together with insulin or sulfonylureas. Patients should seek immediate medical attention if they experience persistent abdominal pain, rash, swelling, or signs of low blood sugar.

Maysiglu should be avoided in individuals with known hypersensitivity to sitagliptin or any component of the formulation, and in patients with severe renal impairment (eGFR < 30 mL/min/1.73 m²) unless dose‑adjusted by a specialist. Caution is also advised for those with a history of pancreatitis.